Geometry Engine is the First Step to Modernizing Hardware Design Tools
Announces $5M Series Seed Financing Led by Venrex Partners
LOS ANGELES, Oct. 3, 2023 — KittyCAD, the world’s only company to develop advanced tools for hardware design, announced today the release of first-ever geometry engine capabilities on their API. The KittyCAD API builds a bridge between hardware design, modern software, and machine learning, allowing others to build on top of these capabilities and develop solutions for their own visions.
Launched in July 2022, KittyCAD’s API enables customers to develop fully integrated suites of hardware design products. In addition to KittyCAD’s API, the company develops open-source applications on top of its own API, which are used by customers as starting points for their own application development. Three of these open-source applications are being built in public by KittyCAD alongside the release of the API’s geometry engine capability: the KittyCAD Scripting Language (KCL), used to programmatically generate hardware designs, the KittyCAD Modeling App (KCMA), a first of its kind GUI for simultaneously interacting with hardware designs through both code and visually in a single environment, and the KittyCAD diff viewer for visualizing differences in CAD files.
“KittyCAD allows modern software development to integrate with hardware design. Our API allows our customer’s software to talk to hardware designs, letting anyone develop hardware design tools on top of us that have never-before-seen capabilities,” says Jordan Noone, KittyCAD’s co-founder and Executive Chairman, who also led Relativity Space’s technical development as CTO and co-founder for five years.
“We’ve seen the power of our own API by developing our own open source applications on top of it, and have surprised ourselves even with how quickly we can develop applications that could not exist before our API,” says Jessie Frazelle, KittyCAD’s co-founder and CEO, who was previously Chief Product Officer at Oxide Computer Company and long-time infrastructure engineer.
Earlier this year, KittyCAD closed a $5M Series Seed financing led by Venrex Partners, a UK-based Venture Capital firm. The round also included participation from USC’s Viterbi School of Engineering, Gaingels, Kelvin Beachum, Matt Terrell, Undeterred Capital, Liquid 2, Tom Preston-Werner’s Family Office, Madrona Venture Group, Bernie Lagrange, and Nat Friedman. The financing series will allow KittyCAD access to funds to continue hiring engineering talent to develop advanced hardware design tools and infrastructure.
ABOUT KITTYCAD KittyCAD develops advanced hardware design tools and infrastructure. KittyCAD was incubated within Embedded Ventures with additional investors including Venrex Partners, USC’s Viterbi School of Engineering, Gaingels, Kelvin Beachum, Matt Terrell, Undeterred Capital, Liquid 2, Tom Preston-Werner’s Family Office, Madrona Venture Group, Bernie Lagrange, and Nat Friedman. KittyCAD is led by co-founders Jordan Noone, Jenna Bryant and Jessie Frazelle.
Company to apply for FDA clearance, expand clinical programs for additional indications and scale manufacturing
LOS GATOS, Calif., Oct. 3, 2023 — Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing. The funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities. The financing was led by The Capital Partnership (TCP) and Cormorant Asset Management, with significant participation from the PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures and Shifamed angel investors.
“Despite the proliferation of mechanical thrombectomy devices, significant challenges remain. The low-profile Akura platform is designed to remove soft and hard clots. Additionally, the system’s continuous monitoring of hemodynamics will allow physicians to assess physiologic changes when a substantial clot has been removed,” said Gautam Kainth, Managing Director, The Capital Partnership. “We are pleased to lead this round and look forward to working with the Akura team to bring this much needed solution to market.”
The Akura Mechanical Thrombectomy Platform is designed to be an easy-to-use, smaller bore system. The low-profile, steerable sheath allows physicians to bring the tip of the catheter directly to the proximal end of the clot without having to cross the clot. The platform’s integrated aspiration and maceration technology, incorporating intersecting jets, aims to enable efficient removal of mixed morphology clots. Additionally, pressure sensors provide real-time hemodynamic data, reducing the guesswork around case progress.
“The Akura thrombectomy platform is designed to provide large-bore catheter performance with a user-friendly system that will change how physicians approach thrombus removal in a clinically meaningful way,” stated Murali Srivathsa, President and Chief Executive Officer, Akura Medical. “We thank our investors for their strong, ongoing support as we continue to execute and deliver on our commitment to advance our differentiated solution for VTE.”
VTE occurs when a blood clot, often formed in a deep vein in the leg, severely restricts or blocks blood flow to the lungs, which can be life-threatening. As many as 900,000 people are affected annually in the US. Estimates suggest that 60,000-100,000 Americans die of VTE per year.1
About Akura Medical, Inc. Akura Medical, a privately held portfolio company of Shifamed LLC, is focused on a differentiated approach delivering an effective solution to address the major challenges of venous thromboembolism (VTE). To learn more about Akura Medical, please visit www.akuramed.com.
The Akura Medical mechanical thrombectomy platform is in the research and development phase and is not FDA cleared, CE Mark approved nor approved for sale worldwide.
About Shifamed, LLC. Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to lead longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.
Partnership with Vista reinforces TRG Screen’s leadership in enterprise subscription spend and usage management; capital will accelerate growth initiatives to address an increasingly complex market data and information environment
NEW YORK, Oct. 3, 2023 — TRG Screen, the leading provider of enterprise subscription spend and usage management software, today announced a strategic growth investment from Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses. TRG Screen will use the capital to accelerate product innovation, talent, and go-to-market functions to meet the growing demand for transparency, compliance, and control of market data and information consumption.
TRG Screen, the leading provider of enterprise subscription spend and usage management software, today announced a strategic growth investment from Vista Equity Partners, a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.
TRG Screen also announced that Leigh Walters has been appointed Chief Executive Officer. Walters, who will succeed Steve Matthews, has previously served as both President and Chief Operating Officer of TRG Screen since joining in 2017. As part of this planned transition, Matthews will assume the role of Executive Chairman after serving as CEO for the past nine years. He will continue to partner with Leigh and the company’s executive team in driving strategic growth.
“This investment from Vista comes following the tremendous success TRG Screen has achieved in providing our customers with leading subscription spend and usage management capabilities; it will also further accelerate our software and managed service offerings in response to the market’s demand for best-in-class solutions,” said Leigh Walters, CEO of TRG Screen.
“Following a successful investment with Pamlico Capital, we are excited to partner with Vista to continue our mission of delivering integrated customer solutions to optimize subscription spend and usage. Vista’s team of investors, operators, and technologists understand the unique opportunity of a company like TRG Screen, and we look forward to working with them in our next phase of growth,” added Steve Matthews, Executive Chairman of TRG Screen.
Driven by an ever-increasing demand for data and information, the subscription landscape continues to grow in both size and complexity, with financial market data alone representing $37.3 billion annual spend in 2022.1 TRG Screen’s modern solutions provide actionable insights into spend and consumption patterns, providing customers with complex and expensive subscriptions with clear visibility into their spend, usage, and compliance, against a backdrop of increased cost pressure. TRG Screen currently serves more than 500 financial services organizations, law firms, and global enterprise customers that jointly manage over $8.5 billion in subscription spend.
“The proliferation of subscription-based services has made controlling costs, monitoring usage, and managing access a top priority for leading financial services organizations, law firms, and global enterprises. TRG Screen’s platform is mission-critical, providing customers with the visibility to make impactful business decisions. We congratulate Steve on positioning TRG Screen to define the future of subscription spend and usage management and are excited to partner with Leigh and the rest of the team to support TRG Screen’s long-term growth and success,” said Martin Taylor, Co-Head of Vista’s Foundation Fund and Senior Managing Director.
“We truly enjoyed working with Steve, Leigh, and the entire TRG Screen team. They are talented operators, and we are thankful to have had the opportunity to help them achieve their vision for the business,” said Walker Simmons, Partner at Pamlico Capital.
Kirkland & Ellis LLP served as legal counsel to Vista, Raymond James served as financial advisor to Vista, and Oliver Wyman served as commercial diligence advisor to Vista. Alston & Bird LLP served as legal advisor and William Blair & Company and Truist Securities served as financial advisors to Pamlico and TRG Screen.
Additional financial terms of the transaction were not disclosed.
About TRG Screen TRG Screen is the leading provider of enterprise subscription management solutions. Founded in 1998, TRG Screen is uniquely differentiated by its ability to monitor both spend and usage of data and information services including market data, research, software licenses, consulting and other corporate expenses. TRG Screen’s solutions provide its customers with full transparency into their vendor relationships and their subscription spend and usage, enabling them to optimize their enterprise subscriptions. TRG acquired Priory Solutions in 2016, Screen Group in 2018, Axon Financial Systems in 2019, Market Data Insights in 2020, and Jordan & Jordan’s Market Data Reporting (MDR) business in 2021 and with these acquisitions is now positioned as the global market leader in the financial, legal, and professional services markets. TRG Screen’s product portfolio includes subscription spend, usage, enquiry and compliance solutions. For more information visit trgscreen.com. Follow TRG Screen on LinkedIn, @TRG Screen, and on Twitter, @trgscreen.
About Vista Equity Partners Vista is a leading global investment firm with more than $100 billion in assets under management as of June 30, 2023. The firm exclusively invests in enterprise software, data and technology-enabled organizations across private equity, permanent capital, credit and public equity strategies, bringing an approach that prioritizes creating enduring market value for the benefit of its global ecosystem of investors, companies, customers and employees. Vista’s investments are anchored by a sizable long-term capital base, experience in structuring technology-oriented transactions and proven, flexible management techniques that drive sustainable growth. Vista believes the transformative power of technology is the key to an even better future – a healthier planet, a smarter economy, a diverse and inclusive community and a broader path to prosperity. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on Twitter, @Vista_Equity.
About Pamlico Capital Pamlico Capital is a private equity firm founded in 1988 that invests in growing middle market companies in North America. Pamlico Capital seeks control-oriented growth equity investments of up to $200 million alongside founders and proven leaders in its target industries: communications, healthcare, services and software. The firm, based in Charlotte, NC, has assets under management of almost $3.5 billion. For additional information, please visit www.pamlicocapital.com.
Media Contact For TRG Screen Roel Mels [email protected] +31 73 6122 940
For Vista Equity Partners Brian Steel [email protected] (212) 804-9170
Round will enable scaling of nationwide network for spray drone services in agriculture
IOWA CITY, Iowa, Oct. 3, 2023 — Rantizo, the leading operator network for spray drone services, announced today an expansion of its oversubscribed Series A funding round. Led by Leaps by Bayer, with Fulcrum Global Capital and Innova Memphis, this round will allow the new executive team to lean into a new growth strategy for Rantizo.
“Our vision is to build a service network that puts autonomy to work in ag, starting with spray drone services. We are excited to expand our nationwide operator network, deploy our work management and as-applied map software, and continue our exponential growth in acres treated,” said CEO Mariah Scott.
Rantizo has more than doubled the total acres flown YoY, with operators in 30 states. Rantizo operators currently fly and apply with more than 20% of the Top 50 ag retailers, using spray drones to provide timely, local and precision application services for crops ranging from Arkansas rice to Iowa corn to Oregon hops and Idaho potatoes, enabling ag retailers to expand their services to growers.
“A common mantra you hear across agriculture is ‘we are going to have to do more, with less.’ We believe that autonomy is the future of modern agriculture, and the Rantizo best-in-class software platform, deep drone operator network, and experienced management team provide acceleration not only for the emerging ‘spraying-as-a-service’ industry but the entire agriculture automation sector as well,” said Kevin Lockett, Partner at Fulcrum Global Capital.
Up to 60% of ag retailers say their number one challenge within their operations is workforce availability. Another top five item on that list is the adoption and use of new technology. Rantizo provides a solution for both with a nationwide operator network, leading drone service and support, and job management software.
“The way Rantizo addresses farmers’ problems by seamlessly integrating drone services into existing workflows is a perfect fit for our FarmTech focused fund,” said Jan Bouten, Partner at Innova Memphis.
“Rantizo has been a great partner in servicing our grower customers. The drones utilized by Rantizo allow us to provide crop inputs on acres that otherwise may miss an application or go untreated due to poor or wet conditions. We look forward to building upon our current successes and growing this partnership across more of our geography,” says Jordan Hart, Regional Operations Manager, Simplot.
This year, Rantizo more than tripled the acres treated for Simplot, a result of the new strategy introduced by CEO Mariah Scott. She joined the company in April, after leading Verizon Robotics and the successful acquisition of Skyward, a drone management company, by Verizon. At Rantizo, she strengthened the executive team, bringing in leaders with extensive experience in software, service operations, agricultural sales and marketing, aviation, drones and finance.
“We are excited about the new leadership team at Rantizo. They bring the deep and diverse experience across drones and agriculture required to effectively deploy the service and deliver on the strategy” said PJ Amini, Sr. Director, Leaps by Bayer.
About Rantizo Rantizo connects demand and supply for agricultural spray drone services with a turnkey service platform. We enable industry leading drone applicators by selling drones, support, software and training, and our service platform connects demand for acres to be sprayed to local operators. Rantizo operators fly and apply in 30 states, providing qualified, licensed, and insured precision application services. Look for us in a field near you or learn more at www.rantizo.com. For media inquiries please contact Brady Eilers.
FARMINGTON, Conn., Oct. 2, 2023 — Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $40 million venture loan facility to Elligo Health Research®, Inc. (“Elligo”), of which $25 million has been initially funded.
Elligo is revolutionizing clinical research with its innovative technology platform, which empowers clients to seamlessly utilize non-traditional clinical trial sites, significantly increasing clients’ access to untapped trial participants. Its data-driven clinical trial recruitment and workflow automation solutions optimize and streamline workflows, while providing users with an integrated and diverse network of relevant clinical trial sites, patients and their own physicians with which to engage. Elligo is backed by premier investors including Morgan Stanley, Ally Bridge Group, Norwest Venture Partners, Piper Sandler, Noro-Moseley Partners and Hatteras Venture Partners. The company will use the loan proceeds for general growth and working capital purposes.
“Elligo’s cutting-edge technology has the potential to solve the patient accessibility issue that has consistently impacted the clinical trial market,” said Gerald A. Michaud, President of Horizon. “With upwards of 95% of physicians and patients not able to participate in clinical trials, Elligo’s platform presents a compelling opportunity to accelerate clinical research, which is a win for the entire healthcare ecosystem. We are pleased to support Elligo in their ongoing efforts to improve the clinical trial system.”
“We are excited to have Horizon’s support as we continue to make great strides in enhancing our adaptive engagement model,” said John Potthoff, Ph.D., Founder and CEO of Elligo. “Our unique workflow automation feature, IntElligo®, in tandem with Elligo’s data capabilities, enables us to facilitate access to more patients and more efficient and cost-effective trials, thus accelerating new therapies and devices to market, which is critical to improving healthcare for all.”
About Horizon Technology Finance
Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S. Monroe Capital is a $17 billion asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity. To learn more, please visit horizontechfinance.com.
About Elligo Health Research®
Elligo Health Research accelerates clinical trials through direct access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites, leveraging EHR data and utilizing our proprietary IntElligo technology. Our PatientSelect® model engages our network of networks to optimize the intersection of healthcare and research and bring more patients clinical research as a care option. Elligo’s SiteSelect model and Research Partner Services enable sites to seamlessly participate in trials, further advancing the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.
Forward-Looking Statements
Statements included herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company’s filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
SAN FRANCISCO, Oct. 2, 2023 — Piccolo Medical, Inc. (Piccolo) today announced the close of a $5.5M Series B financing led by Event Capital Strategies, a medical technology-focused investment fund based in New York. Funding from the Series B will support the further development and commercialization of the Company’s catheter guidance technology, including the next-generation SmartPICC® cathether tip location and navigation system that received 510(k) approval from the FDA in January 2021.
“Now it is time to execute,” said CEO Augustus (Augie) Shanahan who has led the organization since 2022 and has overseen both the development of the long-term strategy of Piccolo and the raising of the additional capital. “With crucial funding in place, we can now deliver Piccolo’s disruptive technology to patients and healthcare providers.” Over 8M central venous access devices are inserted into patients in the U.S. each year and catheter malpositioning can lead to ineffective delivery of life saving drugs as well as thrombosis, cardiac dysfunction and other significant health complications.
Chris Yamamoto, Managing Partner of Event Capital Strategies, has joined Piccolo’s Board of Directors alongside Drs. Mark Healy and Dan Burnett, the founder of the Theranova medical device incubator.
According to Dr. Burnett, “Augie has stepped up and delivered. For a first-time CEO to enter this fundraising climate and secure a multi-year runway is impressive. With his background in engineering, he has the crucial experience needed to develop and launch this technology, and with the SmartPICC® we have the opportunity to make a real difference in patients’ lives. Augie has a long tenure in leadership roles in the Medical Device space. Over the past 15 years, he has brought advanced technologies to the market in vascular access, respiratory care, and orthopedics.”
Dr. Healy added, “We are thrilled that we now have the capital needed to bring this technology to market. This team continues to impress me, most of all, by focusing on helping providers improve patient care. It’s only a matter of time before they demonstrate the true clinical value of the SmartPICC® technology in identifying optimal catheter placement based on ionic dilution.”
About Piccolo Medical: Piccolo Medical Inc. was spun out of the Theranova medical device incubator in San Francisco, CA. It has been funded by private investors as well as prestigious Phase I and II grant awards from the National Institute of Health’s National Institute of Aging. Piccolo received 510(k) clearance for the SmartPICC® System in 2021. Theranova has spun out several other successful medical device companies with products in the US, EU and CN markets.
Leading social AI platform Chai empowers the community to create and experience the world’s most entertaining chat AI.
PALO ALTO, Calif., Oct. 2, 2023 — AI platform Chai today announced that it has closed a strategic investment with CoreWeave, a specialized cloud provider of large-scale GPU-accelerated workloads.
The deal caps Chai’s valuation at $450 million and follows several months on from Chai’s pre-seed round in which it raised $2 million to further the company’s mission of creating a more open and democratic AI platform.
CoreWeave’s strategic investment in Chai will go towards powering one of the first large-scale AI language model competitions, where competitors submit language models to compete for user engagement in Chai’s popular entertainment app. Winners in the competition are rewarded with cash prizes and the prestige of the title.
Chai has also deployed its service on top of CoreWeave’s infrastructure, meaning every message sent on the platform goes through CoreWeave’s cloud.
“CoreWeave has the best insight into the inner workings of our business out of everyone”, said Chai CEO William Beauchamp. “As our user base continues to grow, so will our demand for CoreWeave’s infrastructure offerings”.
The partnership supports affordable, resilient power projects across the US
CHICAGO, Oct. 2, 2023 — Cultivate Power, a distributed solar and storage project developer committed to strengthening communities, the grid, and climate stability, today announced it has secured a corporate equity investment of $10 million from Generate Capital, a leading sustainable investment and operating company driving the infrastructure transition. This investment demonstrates the companies’ shared commitment to deploying distributed clean energy projects that deliver affordable power to communities across the country and boost local economies.
“We have worked with the founders of Cultivate Power for many years and are thrilled to invest in the company to support its growth. Cultivate Power’s strong project portfolio, experienced leadership team and focus on distributed clean power projects align with Generate’s mission to accelerate the infrastructure transition,” said Peggy Flannery, Managing Director at Generate Capital.
The corporate equity commitment from Generate Capital provides Cultivate Power with the resources needed to grow its business. The investment will be used to expand the development of solar and storage projects, recruit top talent, and support local partnerships that benefit the environment and local communities, including scholarship and workforce development programs.
Led by long-time colleagues and renewable energy development professionals Brian Matthay and Noah Hyte, Cultivate Power develops 10- to 50-acre distributed solar and storage projects that generate substantial social and economic impacts in rural communities. Cultivate Power believes that to maximize climate and community benefits, project development must start locally in collaboration with each community.
“Generate is a perfect fit for us. They have a strong track record dating back to their early investment and innovation in community solar markets. They share our belief that carefully developed clean power projects can provide significant community benefits such as low-cost power, increased tax revenue, job training programs, and a wide variety of partnerships and funding for community organizations,” said Noah Hyte, Managing Director of Cultivate Power.
Cultivate Power is headquartered in Chicago, Illinois, with local development teams throughout the Midwest and California. To learn more about Cultivate Power, please visit www.cultivate-power.com. For more information on Generate Capital, please visit https://generatecapital.com/.
About Cultivate Power Cultivate Power is a distributed solar and storage project developer committed to strengthening communities, the grid, and climate stability. The company is uniquely focused on developing 10- to 50-acre solar and storage projects on farmland and infill. Led by long-time renewable energy professionals Brian Matthay and Noah Hyte, Cultivate Power and its in-market development teams operate with the belief that climate challenges can be better addressed by prioritizing the local benefits of distributed clean power. For more information, please visit www.cultivate-power.com.
Investment will drive expansion of new AI platform, in use by Houston Methodist and additional health systems
BOSTON, Oct. 2, 2023 — Health Data Analytics Institute (HDAI)— an artificial intelligence (AI) company focused on empowering clinicians, optimizing care pathways, and improving patient outcomes — today announced an oversubscribed Series C financing to scale its predictive risk platform.
“We are grateful for the continued support of our investors, who recognize the value to be unlocked by transforming huge volumes of health data into actionable insights,” said Nassib Chamoun, Founder and CEO of HDAI. “HDAI is committed to improving patient outcomes and clinician experiences through its broad platform of predictive analytics and AI technologies, and we are thrilled to have secured this additional funding which will allow us to drive continued implementation of our unique HealthVision™ product within top health systems nationwide.”
Several preeminent health systems including Houston Methodist, Cleveland Clinic, and Dana-Farber Cancer Institute, are collaborating with HDAI on various initiatives. HDAI’s implementation at Houston Methodist is one of the most comprehensive, system-wide AI/machine learning (ML) care optimization solutions in production enabling data-informed actions by clinicians at the point of care and by population health managers at the system level. It also represents one of the largest deployments of Generative AI within healthcare. HDAI has additional collaborations with over 40 Medicare Accountable Care Organizations (ACOs) through which it collectively generates 50 million weekly predictions for one million patients.
“While the swirling hype about AI in healthcare continues to generate exciting claims but little of genuine impact, the HDAI team is actively working with leading healthcare organizations and clinicians to improve care in ways that deliver better outcomes,” said Ed Kania, HDAI board member and longtime healthcare investor. “I am increasingly convinced that the Company’s broad-based enterprise platform and remarkably cost-efficient business model can transform healthcare in the US.”
At the core of HDAI’s technology platform is an AI-optimized engine that incorporates explainable machine learning (ML) and Generative AI to quantify patient and population risks and pinpoint actionable clinical improvement opportunities. The platform forecasts health risk at patient, practice, institution and/or regional levels and supports clinicians and institutions in driving performance improvements. For example, HealthVision™ generates customizable lists of patients who would benefit from general case management or specific interventions. It provides a granular analysis of healthcare outcomes and costs as compared to peer practices and institutions. It also provides physicians with a highly synthesized view of individual patients’ medical histories including detailed risk profiles, allowing them to spend more time developing individualized treatment plans and less time searching for information. HDAI augments the direct capabilities of HealthVision™ with experienced clinical teams who provide guidance and support to clinicians and case managers in the development of AI guided workflows.
”HDAI has firmly established itself through key partnerships with some of the top health systems in the country. We are confident that the company has the technology, resources, and team to deliver on the promise of AI in healthcare,” said Philippe Amouyal, managing director at Invus and a lead investor in HDAI. “We look forward to HDAI advancing its mission to enable system-wide efficiencies and improved patient care.”
On Sunday, October 8th, Chamoun will be speaking at the HLTH industry conference in Las Vegas, with Roberta Schwartz, EVP and Chief Innovation Officer of Houston Methodist. In their talk titled “Deploying Clinical AI at Scale,” they will describe Houston Methodist’s system-level embedded predictive AI implementation and related Generative AI capabilities.
Health Data Analytics Institute (HDAI) is a care optimization, decision support and provider enablement company powered by big data, AI-powered analytics, expert insights and point of care technology solutions. The company’s HealthVision™ platform uses predictive analytics and generative AI to analyze a patient’s medical history, including unstructured clinical notes and administrative data, to create a concise summary of the patient’s clinical chart, state of health, and to quantify and prioritize specific clinical risks. HDAI collaborates with leading health systems, value-based care Organizations, physician groups, and payers to improve care delivery, population health and reduce cost and make efficient use of scarce clinical resources. For more information, please visit: www.hda-institute.com.
Invus is an evergreen equity investment platform with approximately 10 billion of capital under management and principal offices in New York, Paris, and Hong Kong. The firm partners with owner-managers who aspire to transform their industries. For more information, please visit: www.invus.com.
